Table 3. Adverse events of patients treated with BRAF inhibitor in combination with radiotherapy.

	Concomitant vemurafenib (n=59)	Interrupted vemurafenib (n=51)	Concomitant dabrafenib (n=28)	Interrupted dabrafenib (n=17)
Radiation dermatitis
1°	11 (19%)	6 (12%)	4 (14%)	2 (12%)
2°	15 (25%)	6 (12%)	4 (14%)	0
3°	6 (10%)	1 (2%)	2 (7%)	0
Other adverse events
Follicular cystic proliferation	10 (17%)a	0	0	0
Hearing disorder	4 (7%)	0	0	0
Dysphagia	2 (3%)	0	0	0
Hyperpigmentation	1 (2%)	3 (6%)	0	0
Impaired wound healing	1 (2%)	0	1 (4%)	0
Haemorrhagic intracranial metastasis	1 (2%)	0	1 (4%)	0
Pneumonitis	1 (2%)	0	1 (4%)	0
Othersa	3 (5%)b	1 (2%)c	0	1 (6%)d

Adverse events appearing in more than one patient in the entire cohort are listed in the table while adverse events occurring in only one patient are summarised in ‘Others’.

^aIncludes one case of cutis verticis gyrate-like toxicity as the maximal form of follicular cystic proliferation.

^bOne case each of cardiac insufficiency, hand-food syndrome and taste disorder

^cRadiation recall dermatitis

^dPruritus.